NCT06971185View on ClinicalTrials.gov

A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept

Active, not recruitingOBSERVATIONAL
Enrollment

430

Participants

Timeline

Start Date

November 22, 2024

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2025

Conditions
Myelodysplastic Syndromes (MDS)
Interventions
DRUG

Luspatercept

As per product label

DRUG

Erythropoiesis-stimulating agent (ESA)

As per product label

Trial Locations (1)

08540-4715

Bristol Myers Squibb, Princeton

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06971185 - A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept | Biotech Hunter | Biotech Hunter